Note that the $3.6B market size is for CVac on Ovarian cancer only. Not to mention that they are chasing down breast cancer too in trials. Plus it may work in a few other cancers. Since the technology is non toxic and has minimal side effects it would be the preferred treatment option by patients and more likely to be backed by government through Medicare like Provenge will be.
Also the other two products in early stage which are likely to get fast tracked as Prima advances with CVac.
For all those worrying about the SP moving up and down 10-20%...just buy up...this share is heading well north longer term. Don't worry about market manipulation and an uneducated biotech Aussie market.
- Forums
- ASX - By Stock
- interesting read - pro active group
Note that the $3.6B market size is for CVac on Ovarian cancer...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $450.9M |
Open | High | Low | Value | Volume |
30.5¢ | 32.0¢ | 30.5¢ | $553.6K | 1.778M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 204215 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 22137 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 210628 | 0.310 |
21 | 496484 | 0.305 |
8 | 155031 | 0.300 |
10 | 139668 | 0.295 |
8 | 152615 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 25460 | 9 |
0.320 | 165687 | 14 |
0.325 | 280126 | 10 |
0.330 | 65414 | 6 |
0.335 | 120295 | 9 |
Last trade - 15.04pm 13/11/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online